Document is current
Any future updates will be listed below
-
Authors
Banerjee, Susana https://orcid.org/0000-0002-8840-7934
Krebs, Matthew G.
Greystoke, Alastair https://orcid.org/0000-0001-9168-0387
Garces, Alvaro Ingles https://orcid.org/0000-0002-0073-4237
Perez, Vicky Sanchez
Terbuch, Angelika https://orcid.org/0000-0003-2918-1370
Shinde, Rajiv
Caldwell, Reece
Grochot, Rafael
Rouhifard, Mahtab https://orcid.org/0009-0006-6118-1097
Ruddle, Ruth https://orcid.org/0000-0003-0025-8872
Gurel, Bora https://orcid.org/0000-0002-5018-8078
Swales, Karen https://orcid.org/0000-0002-6572-1293
Tunariu, Nina
Prout, Toby
Parmar, Mona https://orcid.org/0000-0001-7818-4100
Symeonides, Stefan https://orcid.org/0000-0002-9892-9314
Rekowski, Jan https://orcid.org/0000-0002-5207-3864
Yap, Christina https://orcid.org/0000-0002-6715-2514
Sharp, Adam
Paschalis, Alec
Lopez, Juanita https://orcid.org/0000-0001-8321-4212
Minchom, Anna https://orcid.org/0000-0002-9339-7101
de Bono, Johann Sebastian
Banerji, Udai https://orcid.org/0000-0003-1503-3123
- License Information
-
More Information
Article History
Received: 12 December 2024
Accepted: 7 May 2025
First Online: 27 June 2025
Competing interests
: S.B. has received honoraria for consulting and/or advisory board work from AbbVie, AstraZeneca, BioNTech, Eisai, Gilead, GlaxoSmithKline, Grey Wolf Therapeutics, Immunogen, Incyte, ITM Oncologics, Lilly, Merck Sharpe Dohme, Mersana, Myriad, Oncxerna, Pharmaand, Seagen, TORL BioTherapeutics, Verastem, Zymeworks; honoraria and/or expenses from AbbVie, AstraZeneca, GlaxoSmithKline, Immunogen, Merck Sharpe Dohme, Mersana, Takeda, Verastem and Zymeworks; research funding from AstraZeneca, GlaxoSmithKline; and PI for Global/ENGOT lead RAMP201 and ENGOT lead RAMP301 (Verastem-sponsored). M.G.K. has a consulting or advisory role with Bayer, Guardant Health, Janssen, Roche, Seattle Genetics and Zai Lab; has received speaker fees from BMS, Eisai, Janssen, Roche and Servier; travel, accommodation or expenses from BerGenBio, BMS, Janssen, Roche, Servier and Zai Lab; and research grants from Novartis and Roche. A.G. declares no competing interests. A.I.G. declares no competing interests. V.S.P. declares no competing interests. A.T. declares no competing interests. R.S. has received travel expenses from Bayer and for educational symposia from AstraZeneca. R.C. declares no competing interests. R.G. declares no competing interests. M.R. is an Institute for Cancer Research (ICR) employee. R.R. is an ICR employee. R.G. is an ICR employee. K.S. is an ICR employee. N.T. declares no competing interests. T.P. is an ICR employee. M.P. is an ICR employee. S.S. has received research grants from Verastem Oncology, Merck Sharpe Dohme; advisory board honoraria from Ellipses Pharma and Exscientia/Recursion; and is on the nonremunerated advisory board of Duke Street Bio, Ellipsis, Grey Wolf Therapeutics, Merck Sharp and Dohme and Roche. J.R. has received an advisory board honorarium from Novartis and is an ICR employee. C.Y. is an ICR employee and has received honoraria Faron Pharon Pharmaceuticals, Bayer, Trogenix and Merck. A.S. is an ICR employee; has received travel support from Sanofi, Roche-Genentech and Nurix; honoraria as a speaker from Astellas Pharma and Merck Sharp Dohme; and is on the advisory board of DE Shaw Research, CHARM therapeutics, Ellipses Pharma and Droia Ventures. A.P. declares no competing interests. J.L. has received research grants from Roche-Genentech, Astex, Merck Sharp Dohme, Janssen and Verastem Oncology; and is on the advisory boards of Basilia, Roche, GlaxoSmithKline and Servier. A.M. has received research grants Astex, Merck and Merck Sharp Dohme; honoraria from Chugai, Faron, Merck, GlaxoSmithKline, Seagen, Takeda and Janssen; travel support from Amgen and Janssen; and is on the advisory boards of Imugene, Jansson, Merck, Takeda, Merck Sharp Dohme, Genmab, Pfizer, AstraZeneca and Immutep. J.S.d.B. is an ICR employee, named as an inventor, with no financial interest for patent 8,822,438, submitted by Janssen that covers the use of abiraterone acetate with corticosteroids; has received research support from AstraZeneca, Cellcentric, Crescendo, Daiichi, Immunic Therapeutics, MetaCurUm, Myricx, Nurix, Oncternal, Orion and Sanofi Aventis; honoraria from advisory boards of AbbVie, Acai Therapeutics, Amgen, Amunix, Astellas, Bayer, Bioxcel Therapeutics, Celcuity, Crescendo, Daiichi, Dark Blue Therapeutics, Duke Street Bio, Dunad Therapeutics, Endeavor Biomedicines INC, Genentech-Roche, GSK, Macrogenics, Merck Serono, MetaCurUm, Moma Therapeutics, Myricx, Novartis, Nurix, Nuvation Bio, One-Carbon Therapeutics, Oncternal, Orion, Page Therapeutics, Peptone, Pfizer, Takeda, Tango Therapeutics, Tubulis, GmbH and VIR Biotechnology. U.B. is an ICR employee, named as an inventor on patents arising from this trial, ICR has has entered into a license agreement with Verastem Oncology and UB is due to receive a proportion of income arising from this license in accordance with the institute's rewards to discoverers policy; has received research grants from Verastem Oncology, Chugai and Avacta; and honoraria for advisory board work from Carrick Therapeutics, Pharmenable, Ellipses, Amalus Therapeutics, Dania Therapeutics and Pegascy. The Institute of Cancer Research has commercial interests in CYP17, AKT, CHK1, RAF, MPS1, FLT3/Aurora Kinase inhibitors, GCN2 activators, molecular glues and folate targeted thymidylate synthetase inhibitors.
